1. Zheng N, Fang J, Xue G, Wang Z, Li X, Rahma M, McFadden G, and Yong Lu. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. 2022, 40 (9), 973-985
  2. Xue G, Zheng N, Jing Fang, Jin G, Li X, Dotti G, Qing Y and Yong Lu. Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss variant tumor cells. Cancer Cell. 2021, 39 (12), 1610-1622.
  3. Xue G, W Ziyu, Zheng N, Jing Fang, Mao C, Li X, Jin G, Ming X, and Yong Lu. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumor cells and immunosuppressive cells. Nature Biomedical Engineering. 2021, 5 (11), 1306-1319.
  4. Gang Xue, Guangxu Jin, Jing Fang & Yong Lu. IL-4 together with IL-1β induces antitumor Th9 cell differentiation in the absence of TGF-β signaling. Nature Communications, 2019 Mar 26;10 (1):1376
  5. Yong Lu, Wang Q, Xue Gang, Bi E, Ma X, Wang A, Qian J, Dong C and Yi Q. Th9 cells represent a unique subset of CD4+ T cells endowed with the ability to eradicate advanced tumors. Cancer Cell, 33, 1048–1060; 2018, June 11. PMC6072282